Targeted Entheogen Therapeutics

Fully integrated, pre-clinical stage biotechnology company developing therapeutics for accessible treatment of psychiatric diseases

Our science

PEB leverages the neuroplastic potential of psychoactive molecules from full-spectrum, cell-based extracts 

  • Living library of more than 200 entheogen fungi, plants and animal cells

  • Disease models in major neuropsychiatric disorders

  • Translational research capability to identify doses, schedules and delivery that are accessible and cost effective 

Fully equipped facility including production, extraction and purification and DEA licensed analytical laboratory

Lead indication
Obsessive Compulsive Disorder

Lead candidate, a cell-based full spectrum psilocybin in pre-clinical studies in 5 disease models

World-first production of cell-based 5-MeO-DMT

A seamless entheogen-based therapeutics platform to rapidly progress from strong pre-clinical science to definitive clinical trials

Parow Entheobiosciences

Pipeline

TQ6.jpeg